Compare PCQ & HUMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PCQ | HUMA |
|---|---|---|
| Founded | 2001 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 155.6M | 165.7M |
| IPO Year | 2001 | 2020 |
| Metric | PCQ | HUMA |
|---|---|---|
| Price | $8.01 | $0.55 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $1.64 |
| AVG Volume (30 Days) | 190.2K | ★ 4.7M |
| Earning Date | 01-01-0001 | 11-10-2026 |
| Dividend Yield | ★ 4.63% | N/A |
| EPS Growth | N/A | ★ 79.37 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,038,000.00 |
| Revenue This Year | N/A | $98.07 |
| Revenue Next Year | N/A | $480.72 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.57 | $0.34 |
| 52 Week High | $9.19 | $1.53 |
| Indicator | PCQ | HUMA |
|---|---|---|
| Relative Strength Index (RSI) | 44.49 | 57.22 |
| Support Level | N/A | $0.54 |
| Resistance Level | $9.16 | $0.61 |
| Average True Range (ATR) | 0.11 | 0.06 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 6.36 | 63.88 |
PIMCO California Municipal Income Fund is a closed-end management investment company. It seeks to provide current income exempt from federal, New York State, and New York City income tax. The fund invests across sectors including healthcare, property, education, Natural Gas, and others.
Humacyte Inc is developing a commercial-stage biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.